BridgeBio Oncology Therapeutics (BBOT) vs Immuneering (IMRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Immuneering (IMRX) has outperformed BridgeBio Oncology Therapeutics (BBOT) over the past year, losing 36.9% versus a loss of 73.2%. BridgeBio Oncology Therapeutics is the larger company by market cap ($265.4 million vs $254.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBOT | IMRX |
|---|---|---|
| Share price | $3.31 | $3.94 |
| Market cap | $265.38M | $254.91M |
| 1-day change | -3.22% | +5.35% |
| YTD return | -73.56% | -40.12% |
| 1-year return | -73.24% | -36.86% |
| 5-year return | — | -84.15% |
| EPS (TTM) | $-0.07 | $-0.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.87 | $8.48 |
| 52-week low | $3.27 | $3.60 |
| Distance from 52-week high | -77.74% | -53.54% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +641.69% | +335.79% |
| Average volume | 470.20K | 708.12K |
| Shares outstanding | 80.17M | 64.70M |
| Employees | 88 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMRX has outperformed BBOT by 36.4 percentage points over the past year.
About BridgeBio Oncology Therapeutics
BBOT stock →BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
BBOT vs IMRX FAQ
Which is bigger, BridgeBio Oncology Therapeutics or Immuneering?
BridgeBio Oncology Therapeutics (BBOT) is larger, with a market capitalization of $265.38M compared with $254.91M for Immuneering (IMRX).
Which stock has performed better over the past year, BBOT or IMRX?
IMRX returned -36.86% over the past 12 months, compared with -73.24% for BBOT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Oncology Therapeutics and Immuneering in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.